HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells

Danielle M. Pineda, David W. Rittenhouse, Christopher C. Valley, Joseph A. Cozzitorto, Richard A. Burkhart, Benjamin Leiby, Jordan M. Winter, Matthew C. Weber, Eric R. Londin, Isidore Rigoutsos, Charles J. Yeo, Myriam Gorospe, Agnieska K. Witkiewicz, Jonathan N. Sachs, Jonathan R. Brody

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Apoptosis is one of the core signaling pathways disrupted in pancreatic ductal adenocarcinoma (PDA). Death receptor 5 (DR5) is a member of the tumor necrosis factor (TNF)-receptor superfamily that is expressed in cancer cells. Binding of TNF-related apoptosis-inducing ligand (TRAIL) to DR5 is a potent trigger of the extrinsic apoptotic pathway, and numerous clinical trials are based on DR5-targeted therapies for cancer, including PDA. Human antigen R (HuR), an RNA-binding protein, regulates a select number of transcripts under stress conditions. Here we report that HuR translocates from the nucleus to the cytoplasm of PDA cells upon treatment with a DR5 agonist. High doses of DR5 agonist induce cleavage of both HuR and caspase 8. HuR binds to DR5 mRNA at the 5″-untranslated region (UTR) in PDA cells in response to different cancer-associated stressors and subsequently represses DR5 protein expression; silencing HuR augments DR5 protein production by enabling its translation and thus enhances apoptosis. In PDA specimens (n = 53), negative HuR cytoplasmic expression correlated with elevated DR5 expression (odds ratio 16.1, p < 0.0001). Together, these data demonstrate a feedback mechanism elicited by HuR-mediated repression of the key apoptotic membrane protein DR5.

Original languageEnglish (US)
Pages (from-to)946-955
Number of pages10
JournalCancer Biology and Therapy
Volume13
Issue number10
DOIs
StatePublished - Aug 2012

Fingerprint

TNF-Related Apoptosis-Inducing Ligand Receptors
Pancreatic Neoplasms
Antigens
Adenocarcinoma
Apoptosis
RNA-Binding Proteins
Caspase 8
Tumor Necrosis Factor Receptors
5' Untranslated Regions
Neoplasms
Membrane Proteins
Cytoplasm
Proteins
Tumor Necrosis Factor-alpha
Odds Ratio
Clinical Trials

Keywords

  • Apoptosis
  • DR5
  • Pancreatic cancer
  • Pancreatic ductal adenocarcinoma
  • Post-transcriptional regulation
  • TRAIL
  • TRAIL-resistance
  • TRAILR2

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Pineda, D. M., Rittenhouse, D. W., Valley, C. C., Cozzitorto, J. A., Burkhart, R. A., Leiby, B., ... Brody, J. R. (2012). HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells. Cancer Biology and Therapy, 13(10), 946-955. https://doi.org/10.4161/cbt.20952

HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells. / Pineda, Danielle M.; Rittenhouse, David W.; Valley, Christopher C.; Cozzitorto, Joseph A.; Burkhart, Richard A.; Leiby, Benjamin; Winter, Jordan M.; Weber, Matthew C.; Londin, Eric R.; Rigoutsos, Isidore; Yeo, Charles J.; Gorospe, Myriam; Witkiewicz, Agnieska K.; Sachs, Jonathan N.; Brody, Jonathan R.

In: Cancer Biology and Therapy, Vol. 13, No. 10, 08.2012, p. 946-955.

Research output: Contribution to journalArticle

Pineda, DM, Rittenhouse, DW, Valley, CC, Cozzitorto, JA, Burkhart, RA, Leiby, B, Winter, JM, Weber, MC, Londin, ER, Rigoutsos, I, Yeo, CJ, Gorospe, M, Witkiewicz, AK, Sachs, JN & Brody, JR 2012, 'HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells', Cancer Biology and Therapy, vol. 13, no. 10, pp. 946-955. https://doi.org/10.4161/cbt.20952
Pineda DM, Rittenhouse DW, Valley CC, Cozzitorto JA, Burkhart RA, Leiby B et al. HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells. Cancer Biology and Therapy. 2012 Aug;13(10):946-955. https://doi.org/10.4161/cbt.20952
Pineda, Danielle M. ; Rittenhouse, David W. ; Valley, Christopher C. ; Cozzitorto, Joseph A. ; Burkhart, Richard A. ; Leiby, Benjamin ; Winter, Jordan M. ; Weber, Matthew C. ; Londin, Eric R. ; Rigoutsos, Isidore ; Yeo, Charles J. ; Gorospe, Myriam ; Witkiewicz, Agnieska K. ; Sachs, Jonathan N. ; Brody, Jonathan R. / HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells. In: Cancer Biology and Therapy. 2012 ; Vol. 13, No. 10. pp. 946-955.
@article{042e5701b23e42afa535abc99631df59,
title = "HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells",
abstract = "Apoptosis is one of the core signaling pathways disrupted in pancreatic ductal adenocarcinoma (PDA). Death receptor 5 (DR5) is a member of the tumor necrosis factor (TNF)-receptor superfamily that is expressed in cancer cells. Binding of TNF-related apoptosis-inducing ligand (TRAIL) to DR5 is a potent trigger of the extrinsic apoptotic pathway, and numerous clinical trials are based on DR5-targeted therapies for cancer, including PDA. Human antigen R (HuR), an RNA-binding protein, regulates a select number of transcripts under stress conditions. Here we report that HuR translocates from the nucleus to the cytoplasm of PDA cells upon treatment with a DR5 agonist. High doses of DR5 agonist induce cleavage of both HuR and caspase 8. HuR binds to DR5 mRNA at the 5″-untranslated region (UTR) in PDA cells in response to different cancer-associated stressors and subsequently represses DR5 protein expression; silencing HuR augments DR5 protein production by enabling its translation and thus enhances apoptosis. In PDA specimens (n = 53), negative HuR cytoplasmic expression correlated with elevated DR5 expression (odds ratio 16.1, p < 0.0001). Together, these data demonstrate a feedback mechanism elicited by HuR-mediated repression of the key apoptotic membrane protein DR5.",
keywords = "Apoptosis, DR5, Pancreatic cancer, Pancreatic ductal adenocarcinoma, Post-transcriptional regulation, TRAIL, TRAIL-resistance, TRAILR2",
author = "Pineda, {Danielle M.} and Rittenhouse, {David W.} and Valley, {Christopher C.} and Cozzitorto, {Joseph A.} and Burkhart, {Richard A.} and Benjamin Leiby and Winter, {Jordan M.} and Weber, {Matthew C.} and Londin, {Eric R.} and Isidore Rigoutsos and Yeo, {Charles J.} and Myriam Gorospe and Witkiewicz, {Agnieska K.} and Sachs, {Jonathan N.} and Brody, {Jonathan R.}",
year = "2012",
month = "8",
doi = "10.4161/cbt.20952",
language = "English (US)",
volume = "13",
pages = "946--955",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "10",

}

TY - JOUR

T1 - HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells

AU - Pineda, Danielle M.

AU - Rittenhouse, David W.

AU - Valley, Christopher C.

AU - Cozzitorto, Joseph A.

AU - Burkhart, Richard A.

AU - Leiby, Benjamin

AU - Winter, Jordan M.

AU - Weber, Matthew C.

AU - Londin, Eric R.

AU - Rigoutsos, Isidore

AU - Yeo, Charles J.

AU - Gorospe, Myriam

AU - Witkiewicz, Agnieska K.

AU - Sachs, Jonathan N.

AU - Brody, Jonathan R.

PY - 2012/8

Y1 - 2012/8

N2 - Apoptosis is one of the core signaling pathways disrupted in pancreatic ductal adenocarcinoma (PDA). Death receptor 5 (DR5) is a member of the tumor necrosis factor (TNF)-receptor superfamily that is expressed in cancer cells. Binding of TNF-related apoptosis-inducing ligand (TRAIL) to DR5 is a potent trigger of the extrinsic apoptotic pathway, and numerous clinical trials are based on DR5-targeted therapies for cancer, including PDA. Human antigen R (HuR), an RNA-binding protein, regulates a select number of transcripts under stress conditions. Here we report that HuR translocates from the nucleus to the cytoplasm of PDA cells upon treatment with a DR5 agonist. High doses of DR5 agonist induce cleavage of both HuR and caspase 8. HuR binds to DR5 mRNA at the 5″-untranslated region (UTR) in PDA cells in response to different cancer-associated stressors and subsequently represses DR5 protein expression; silencing HuR augments DR5 protein production by enabling its translation and thus enhances apoptosis. In PDA specimens (n = 53), negative HuR cytoplasmic expression correlated with elevated DR5 expression (odds ratio 16.1, p < 0.0001). Together, these data demonstrate a feedback mechanism elicited by HuR-mediated repression of the key apoptotic membrane protein DR5.

AB - Apoptosis is one of the core signaling pathways disrupted in pancreatic ductal adenocarcinoma (PDA). Death receptor 5 (DR5) is a member of the tumor necrosis factor (TNF)-receptor superfamily that is expressed in cancer cells. Binding of TNF-related apoptosis-inducing ligand (TRAIL) to DR5 is a potent trigger of the extrinsic apoptotic pathway, and numerous clinical trials are based on DR5-targeted therapies for cancer, including PDA. Human antigen R (HuR), an RNA-binding protein, regulates a select number of transcripts under stress conditions. Here we report that HuR translocates from the nucleus to the cytoplasm of PDA cells upon treatment with a DR5 agonist. High doses of DR5 agonist induce cleavage of both HuR and caspase 8. HuR binds to DR5 mRNA at the 5″-untranslated region (UTR) in PDA cells in response to different cancer-associated stressors and subsequently represses DR5 protein expression; silencing HuR augments DR5 protein production by enabling its translation and thus enhances apoptosis. In PDA specimens (n = 53), negative HuR cytoplasmic expression correlated with elevated DR5 expression (odds ratio 16.1, p < 0.0001). Together, these data demonstrate a feedback mechanism elicited by HuR-mediated repression of the key apoptotic membrane protein DR5.

KW - Apoptosis

KW - DR5

KW - Pancreatic cancer

KW - Pancreatic ductal adenocarcinoma

KW - Post-transcriptional regulation

KW - TRAIL

KW - TRAIL-resistance

KW - TRAILR2

UR - http://www.scopus.com/inward/record.url?scp=84864539012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864539012&partnerID=8YFLogxK

U2 - 10.4161/cbt.20952

DO - 10.4161/cbt.20952

M3 - Article

C2 - 22785201

AN - SCOPUS:84864539012

VL - 13

SP - 946

EP - 955

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 10

ER -